Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2022-04-11 Director's Dealing
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Mandatory notification of trade by CEO Christer L. Valderhaug
Director's Dealing Classification · 100% confidence The document explicitly states it is a "Mandatory notification of trade by CEO Christer L. Valderhaug." It details the purchase of shares by an executive and references disclosure requirements under MAR article 19, which governs insider transactions. This directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions an 'attached notification,' the core content is the insider trade disclosure itself, making DIRS the most specific fit over a general RPA or RNS.
2022-04-11 English
Arctic Bioscience publishes 2021 annual report
Annual Report Classification · 100% confidence The document is clearly identified as an 'ANNUAL REPORT 2021' for Arctic Bioscience AS. It contains comprehensive sections including a letter from the CEO, board of directors' report, financial statements (revenue statement, balance sheet, cash flow), notes to the financial statements, and an auditor's report. This aligns perfectly with the definition of an Annual Report (10-K). FY 2021
2022-04-07 English
Arctic Bioscience publishes 2021 annual report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2650 characters) stating that the 2021 Annual Report has been released and is attached to the notice. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). FY 2021
2022-04-07 English
Arctic Bioscience announces full year 2021 results
Earnings Release Classification · 99% confidence The document is titled "Arctic Bioscience announces full year 2021 results" and contains detailed financial tables (Revenues, EBITDA, Cash holdings) for the years 2021 and 2020, along with CEO commentary and a strategic outlook for 2022. This content structure is characteristic of an Earnings Release (ER) or a summary preceding a full Annual Report (10-K). Since it focuses on summarizing the period's results and financial highlights immediately following the period end, it fits the definition of an Earnings Release (ER). Although it mentions the '2021 annual report' in the webcast section, the document itself is the announcement/summary of those results, not the comprehensive 10-K filing. The length (6718 chars) is substantial but the focus is on key highlights and financial summaries, typical of an ER. FY 2021
2022-04-07 English
Arctic Bioscience announces full year 2021 results
Earnings Release Classification · 100% confidence The document is titled "Arctic Bioscience announces full year 2021 results" and contains a summary of financial highlights (Revenues, EBITDA, Cash holdings) for the year 2021 compared to 2020, along with commentary from the CEO and an outlook. This structure strongly indicates an announcement of periodic financial results. Since it covers the full year, it relates to the Annual Report cycle, but the text itself is a summary announcement, not the comprehensive 10-K filing. The document explicitly mentions a "Webcast presentation of 2021 annual report and full year results" scheduled for today, which confirms this is the preliminary release accompanying the full annual report. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is too detailed for just an RPA, and it is not the full 10-K. FY 2021
2022-04-07 English
Arctic Bioscience - Invitation to presentation of Full Year 2021 results
Report Publication Announcement Classification · 98% confidence The document is titled "Arctic Bioscience - Invitation to presentation of Full Year 2021 results" and explicitly states that the company will publish its financial results for FY 2021 on a specific date, followed by hosting a webcast presentation with Q&A. This document is not the financial report itself (like 10-K or IR), but rather an announcement about the upcoming publication of results and the associated presentation/call. According to Rule 2, when a document announces the release of a report and provides details for an associated event (like a webcast/Q&A), it fits the description of a Report Publication Announcement (RPA). It is announcing the publication of the FY 2021 results and inviting participation in the presentation.
2022-03-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.